COVID-19 Impact Analysis on North America Induced Pluripotent Stem Cells Market
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the North America induced pluripotent stem cells market. In addition, complete analysis of changes on the North America induced pluripotent stem cells market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The pandemic slackened the economic growth of various countries comprising the U.S., Canada and Mexico. It also resulted in control measures which impacted operations in life science organizations such as production and research. In an article published by Nature Biotechnology, the CEO of flagship Pioneering stated that lab productivity at many of its research-based setup was running at just 30-50% capacity, and even upholding that rate was a challenge. More than 750 trials of cell and gene therapy in almost 30,000 patients were underway as of June 2020, and CGT products account for some 12% of the pharmaceutical industry’s clinical pipeline and at least 16% of its preclinical pipeline. As per the GEP Worldwide, more than 1,200 clinical trials worldwide were disrupted by June 2020. Nearly 61% of clinical trials were disrupted owing to the suspension of patient enrolment. The impact varied owing to changes in COVID-19 case volume throughout the year, but the worst effect was seen in April 2020. Trials involving respiratory diseases, oncology, ID/anti-infectives and cardiovascular diseases were the worst-hit during this time.
Market Overview- North America Induced Pluripotent Stem Cells Market
Induced pluripotent stem cells market is in emerging state mainly due to its ability to make any cell or tissue the body might need to encounter wide range of diseases like diabetes, spinal cord injury, leukaemia or heart disease, these cells can potentially be customized to provide a perfect genetic match for any patient. Furthermore, these cells are very useful in understanding the earliest stage of human development and offer the opportunity to create customized, rejection-proof cells and tissues for transplantation. Also, government and private sectors are increasing funding and growing industry that focuses on different research work related to induced pluripotent stem cells and people are getting more aware about the stem cells through different organisations.
In the recent years, the complexity of products requested by researchers has grown and this suggests improvement in understanding of the basic pathways and discovery of some new pathways. It is important for manufacturers of research products to keep up with the latest developments to cater to the ever-changing requirements of the life sciences industry.
Stem cell research is attracting wide attention as a promising and fast-growing field in North America, as it is worldwide. Many countries in the region have defined Regenerative Medicine as a research priority and a focus of investment. This field generates not only opportunities but also regulatory, technical and operative challenges. Latin America is a fast-growing region conscious of the relevance of stem cell research for the development of Regenerative Medicine, which we think will play a major role in healthcare.
However, factors such as high cost associated with the reprograming of cells, ethical issues and lengthy processes are impeding the induced pluripotent stem cells market growth. Low efficiency, potential tumour risk and incomplete programming are added factors limiting induced pluripotent stem cells market growth.
Stem cell therapy comprises a modern technology whose aim is to replace damaged cells with healthy new ones. Cells are rendered dysfunctional due to any number of factors such as aging, disease, genetic modification, injury. Currently, Stem cell therapies are providing substantial benefit to patients suffering a wide range of diseases such as cancer, non-cancer, neuronal disease, diabetes and injuries such as brain trauma and spinal cord injuries. It is well established and rapidly growing in developed country however in developing country, there are several challenges which is shielding the booming of this therapy. Owing to that, it is expected to eventually remove these challenges to create the fresh environment of modern stem cell therapeutic medicine.
Cumulative Growth Analysis
The report provides in-depth analysis of North America induced pluripotent stem cells market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. With increasing demand for various induced pluripotent stem cells in various applications has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2022-2028.
Market Segmental Overview
The North America induced pluripotent stem cells market comprises of different market segment like derived cell type, product, processes, application, end user and Country.
North America Induced Pluripotent Stem Cells Market by Derived Cell Type
The various derived cell types comprised in the reports are hepatocytes, fibroblasts, keratinocytes and amniotic cells. The fibroblasts segment is likely to witness the fastest growth during the forecast period. Dermal fibroblasts are also one of the cells types from which induced pluripotent stem cells can be derived. Introduction of certain cellular factors converts human fibroblasts to cells with pluripotent potential, termed induced pluripotent stem cells. Induced pluripotent stem cells can then be induced to differentiate using various differentiation programs. Induced pluripotent stem cells have significant implications for disease therapy: they can be differentiated into multiple lineages and are derived from adult tissue, so are not immunoreactive.
North America Induced Pluripotent Stem Cells Market by Product
The different products comprised in the North America induced pluripotent stem cells market is instruments/devices, automated platforms, consumable and kits and services. The instruments/devices have the potential to help in induced pluripotent stem cells generation by regulating the kinetics of reprogramming factor delivery. A considerable number of players are offering instruments/devices under this segment. For example, Lonza offers Nucleofector transfection technology for efficient transfection of neurons, stem cells, primary cells, and cell lines. The company offered 4-D Nucleofector X Unit and 4D- Nucleofector Y Unit. 4-D Nucleofector X Unit helps with the nucleofection process of different cell numbers in different formats.
North America Induced Pluripotent Stem Cells Market by Process
The various processes comprise in the North America induced pluripotent stem cells market are automated and manual. Increasing demand for reproducible large-scale stem cell and differentiated progeny production, with minimum variation, propels the demand for automation platforms. Several countries have started initiatives for induced pluripotent stem cells line collection to facilitate studies of numerous conditions, including diabetes and cardiovascular and neurodegenerative diseases. Several of these initiatives plan to use automated systems to achieve their goal. For example, various consortiums in Europe aim to develop induced pluripotent stem cells biobank for different diseases. The European Bank for induced Pluripotent Stem Cells (EBiSC) design a bank for more than 10,000 lines covering a wide range of disorders.
North America Induced Pluripotent Stem Cells Market by Application
Based on application, the North America induced pluripotent stem cells market is segmented into drug development and discovery, toxicity screening and regenerative medicine. The toxicity screening is anticipated to witness the fastest growth during the forecast period. The development of human-induced pluripotent stem cell–derived cardiomyocytes has opened a new era to address the challenge of improving drug-induced cardiotoxicity prediction. Human iPSC-CMs can be generated from individuals with diverse genetic backgrounds and varying disease status, which provides unique opportunities to assess drug-induced cardiotoxicity at the population level, ultimately, realizing personalized cardiac safety prediction and permitting mechanistic insights into genetic predisposition of drug-induced cardiotoxicity at the molecular and cellular levels.
North America Induced Pluripotent Stem Cells Market by End User
The various end users comprised in the North America induced pluripotent stem cells market are hospitals, research laboratories and academic research. The research laboratories segment is likely to witness fastest growth during the forecast period. A research institute, research center or research center is an establishment founded for doing research. Research institutes are specialized in basic research or may be oriented to applied research. Although the term often implies natural science research, there are also many research institutes in the social science as well especially for sociological and historical research purposes.
North America Induced Pluripotent Stem Cells Market by Country
The North America induced pluripotent stem cells market report analyses various countries such as U.S., Mexico and Canada. The United States is anticipated to dominate the market in 2021. Followed by Mexico and Canada. The large share of the U.S. market is attributed to the rising incidence of cancer and growing research activity in cancer and stem cells. The rising investment in pharmaceutical R&D is also boosting growth of induced pluripotent stem cells market.
Competitive Landscape Analysis
The competitive landscape analysis of North America induced pluripotent stem cells market is certainly based range of market players operating in the healthcare market with increasing demand for production of induced pluripotent stem cells market. Besides, number of market players offered wide range of products for different application in various geographic locations. The market has major competitive analysis based on new product launches as well as other developments.
The key players studied in market are Fujifilm Holding Corporation, Astellas Pharma Inc., Fate Therapeutics, Inc., Bristol-Myers Squibb Company, ViaCyte, Inc., Celgene Corporation, Aastrom Biosciences, Inc., Acelity Holdings, Inc., StemCells, Inc., Japan Tissue Engineering Co. Ltd. and Organogenesis Inc. among others.
June 2021: Thermo Fisher Scientific Inc. announced that it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company footprints in global market and leading to upsurge company growth in the upcoming years.
June 2020: The LumaCyte collaborated with Catalent who are the global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. This collaboration aided in expanding the company stem cell technology product Radiance and its application.